Q1 2025 Jubilant Ingrevia Ltd Earnings Call Transcript
Key Points
- Jubilant Ingrevia Ltd (BOM:543271) reported a healthy sequential performance for Q1 FY25, driven by improving business performance in the Specialty Chemical segment and cost initiatives.
- The company witnessed rising demand in the pharmaceutical end-use segment with healthy volume placements, particularly in regulated markets like North America, Europe, and Japan.
- The Nutrition segment saw steady demand and marginal price improvements towards the end of the quarter, except for Choline.
- The company’s manufacturing facility at Bharuch successfully completed its USFDA inspection with zero 483 observations, enhancing its credibility in regulated markets.
- Jubilant Ingrevia Ltd (BOM:543271) is on track with its CapEx plans, focusing on high-potential product categories and aiming for significant revenue and EBITDA growth over the next five years.
- The company is facing continuous pressure on the ephedrine segment due to lower demand from the paracetamol end-use segment.
- The Agrochem sector, despite showing marginal improvement, is still under pricing pressure due to excess global supply.
- In the Nutrition segment, Choline prices remained subdued, impacting overall profitability.
- The Chemical Intermediates business experienced lower revenue due to marginally lower volumes and muted prices, affecting overall financial performance.
- Higher ocean freight costs and lower acetic acid prices posed challenges in maintaining market share and profitability in the acetyls segment.
Ladies and gentlemen, good day and welcome to Jubilant Ingrevia's, Q1 FY25 earnings conference call.
(Operator Instructions). Please note that this conference is being recorded. I now hand the conference over to Mr. Paveeln Taneja, Head of Investor Relations, Jubilant Ingrivia Limited. Thank you over to you, Mr. Taneja.
Thank you, (inaudible). Good evening, everyone. Thank you for being with us on our quarter one of financial year 2025 earnings conference call of Jubilant Ingrevia Limited. I would like to remind you that some of the statements made on the call today will be forward-looking in nature, and a detailed disclaimer in this regard has been included in the press release and results presentation that has been shared on our website.
On the call today we have Mr. Shyam Bhartia, Chairman; Mr. Hari Bhartia, Co-Chairman; Mr. Deepak Jain, CEO and Managing Director; and Mr. (inaudible) Group CFO, Jubilant Ingrevia. I now invite Mr. Shyam Bhartia to share his comments. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
